NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer’s disease. The randomized, placebo-controlled study will assess the drug’s symptomatic and potential disease-modifying effects over 18 months. Following positive Phase 2/3 results, the trial received FDA approval and aims to enroll over 750 participants across approximately 100 U.S. sites. The company recently secured $21 million in funding to support the initial six-month phase, with the remaining study expected to be funded through warrant exercises. To view the full press release, visit https://nnw.fm/BTymN About Annovis Bio Inc.…







